Last reviewed · How we verify
Canagliflozin 300 mg
At a glance
| Generic name | Canagliflozin 300 mg |
|---|---|
| Also known as | JNJ-28431754, Invokana 300 mg |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Canagliflozin in Advanced CKD (PHASE4)
- Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis (PHASE2)
- Genetics of Response to Canagliflozin (PHASE1)
- Canagliflozin in Advanced Renal Disease With MRI Endpoints (PHASE2)
- Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer (PHASE2)
- Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer (PHASE1)
- A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus (PHASE3)
- Canagliflozin-Mealtime Insulin Rescue (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Canagliflozin 300 mg CI brief — competitive landscape report
- Canagliflozin 300 mg updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI